Drugs already being used to treat high blood pressure and cholesterol could reduce the risk of Alzheimer’s disease and dementia, according to a new Schaeffer Center study of nearly 700,000 Medicare beneficiaries.
Lifespan Health and Aging
Other featured articles
Conflicts of Interest in Dialysis: A Barrier to Policy Reforms
What are the possible benefits and risks of nephrologist’s financial participation in dialysis facility joint venture (JV) arrangements and financial participation in End‐stage Kidney Disease Seamless Care Organizations (ESCOs)? Eugene Lin and co-authors examine possible mechanisms for disclosure and reporting of such arrangements as well as risk mitigation.
Four Years Into MACRA: What Has Changed?
Changes to nephrology reimbursement present a unique opportunity to improve patient outcomes in a cost‐effective way. A multidisciplinary effort among policy makers, nephrology providers, and patient advocacy groups is critical to ensure these changes in care delivery safeguard and improve patient health.
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Research by Jakub Hlavka and colleagues suggests a combination of brief cognitive tests and blood-based biomarker tests will allow primary care physicians to identify patients with potential early stage Alzheimer’s disease efficiently and triage them for further evaluation.
About this section
People are living longer, which brings obvious benefits as well as considerable challenges — from Alzheimer’s and other age-related diseases to increased injuries, disabilities and poverty risks. Policymakers around the world rely on Schaeffer Center research and modeling tools for finding ways to help keep people as healthy as possible throughout their lives.